Literature DB >> 11560944

CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

M Febbraio1, D P Hajjar, R L Silverstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11560944      PMCID： PMC200943          DOI： 10.1172/JCI14006

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  49 in total

1.  Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma.

Authors:  J Han; D P Hajjar; J M Tauras; J Feng; A M Gotto; A C Nicholson
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

2.  Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition.

Authors:  M K Chang; C Bergmark; A Laurila; S Hörkkö; K H Han; P Friedman; E A Dennis; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

3.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro.

Authors:  E A Podrez; D Schmitt; H F Hoff; S L Hazen
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

5.  A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism.

Authors:  M Febbraio; N A Abumrad; D P Hajjar; K Sharma; W Cheng; S F Pearce; R L Silverstein
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

6.  Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.

Authors:  J T Huang; J S Welch; M Ricote; C J Binder; T M Willson; C Kelly; J L Witztum; C D Funk; D Conrad; C K Glass
Journal:  Nature       Date:  1999-07-22       Impact factor: 49.962

7.  Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells.

Authors:  D A Bird; K L Gillotte; S Hörkkö; P Friedman; E A Dennis; J L Witztum; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

8.  Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin.

Authors:  A Ibrahimi; A Bonen; W D Blinn; T Hajri; X Li; K Zhong; R Cameron; N A Abumrad
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

9.  Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency.

Authors:  E H Hwang; J Taki; S Yasue; M Fujimoto; M Taniguchi; I Matsunari; K Nakajima; S Shiobara; T Ikeda; N Tonami
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

10.  Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells.

Authors:  N C Franc; J L Dimarcq; M Lagueux; J Hoffmann; R A Ezekowitz
Journal:  Immunity       Date:  1996-05       Impact factor: 31.745
View more
  393 in total

Review 1.  Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems.

Authors:  M Krieger
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Series introduction: multiligand receptors and human disease.

Authors:  M Krieger; D M Stern
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  Targeting CD36: modulating inflammation and atherogenesis.

Authors:  David P Hajjar; Antonio M Gotto
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

4.  Giant membrane vesicles as a model to study cellular substrate uptake dissected from metabolism.

Authors:  D P Y Koonen; W A Coumans; Y Arumugam; A Bonen; J F C Glatz; J J F P Luiken
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

Review 5.  HIV protease inhibitors and atherosclerosis.

Authors:  David Y Hui
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

6.  Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases.

Authors:  Stephan Seeliger; Thomas Vogl; Ingo Hubert Engels; J Michael Schröder; Clemens Sorg; Cord Sunderkötter; Johannes Roth
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

7.  CD36 is involved in astrocyte activation and astroglial scar formation.

Authors:  Yi Bao; Luye Qin; Eunhee Kim; Sangram Bhosle; Hengchang Guo; Maria Febbraio; Renee E Haskew-Layton; Rajiv Ratan; Sunghee Cho
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-18       Impact factor: 6.200

8.  ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity.

Authors:  J Dubail; F Kesteloot; C Deroanne; P Motte; V Lambert; J-M Rakic; C Lapière; B Nusgens; A Colige
Journal:  Cell Mol Life Sci       Date:  2010-06-24       Impact factor: 9.261

9.  Fungal pathogen recognition by scavenger receptors in nematodes and mammals.

Authors:  Terry K Means
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

10.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.